Intravitreal Bevacizumab for Neovascular Glaucoma
Not Applicable
Completed
- Conditions
- NeovascularGlaucoma
- Interventions
- Other: subconjunctival normal saline
- Registration Number
- NCT00384631
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
- Clinical diagnosis of NVG
- Vision less than 20/200
- age 10-80 years
Exclusion Criteria
- Uncontrolled Blood Pressure
- History of thromboembolism
- Congestive Heart Failure
- Renal Failure
- Pregnancy or Lactation
- Active ocular or periocular infection
- No light perception
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 subconjunctival normal saline - 1 Avastin -
- Primary Outcome Measures
Name Time Method Change in intraocular pressure 6 months Change in extent of iris neovascularization 6 months
- Secondary Outcome Measures
Name Time Method Best corrected visual acuity 6 months
Trial Locations
- Locations (1)
Labbafinejad Medical Center
馃嚠馃嚪Tehran, Iran, Islamic Republic of